Alkermes Insider Trading: CEO and EVP R&D Show Balanced Buy‑Sell Pattern Amid Bullish Market Momentum

Insider Activity at Alkermes PLC: What the Latest Deals Reveal

A New Deal in a Bullish Market On April 1, 2026, EVP R&D and Chief Medical Officer Craig Hopkinson executed a 5,000‑share purchase at $19.34 under a Rule 10b‑5 Plan, adding to a sizable holding of 94,389 shares. The transaction occurs amid a market backdrop where Alkermes shares have climbed 23 % this week and are trading near their 52‑week high of $36.32. The buy‑side move, combined with a modest 0.01 % price drop, suggests the plan is a routine execution rather than a signal of insider confidence.

Patterns of Buying and Selling Hopkinson’s recent activity shows a consistent mix of purchases and sales. Over the last month, he has bought roughly 25 k shares and sold about 24 k shares, often at prices near the current market level. His 10‑b5 plan, adopted on March 14, 2025, provides a disciplined framework that mitigates timing risk. Importantly, the average price for his sales ($35.51) exceeds the purchase price ($19.34), indicating that his trades are not driven by short‑term speculation but rather by the long‑term value he sees in the company.

Implications for Investors The balanced trade pattern signals a lack of sudden confidence swings. For investors, this points to a stable insider stance: Hopkinson is neither aggressively bullish nor bearish. However, his substantial equity stake—over 85 k shares—means his actions still carry weight. A continued trend of buying could be interpreted as a vote of confidence in Alkermes’ pipeline, particularly its CNS and infectious disease assets, while frequent sales might signal portfolio rebalancing rather than a loss of faith.

Hopkinson Craig C.: A Profile of the Insider Craig Hopkinson, 52, joined Alkermes in 2013 and rose to EVP R&D and Chief Medical Officer. He holds a Ph.D. in Neuroscience from MIT and has led several phase‑III trials for addiction therapies. His insider history shows a preference for plan‑based trades, a moderate overall return on his holdings, and a tendency to lock in gains through sales at peak prices. He rarely engages in large, unplanned sales, suggesting disciplined risk management.

Broader Insider Context Other senior executives, including CFO Joshua Reed and COO Curtis, also employ 10‑b5 plans and have mixed buy‑sell activity. The CEO, Richard Pops, has been predominantly buying, reinforcing a cautious bullish outlook. Across the board, insider activity reflects a consensus that Alkermes’ long‑term prospects—especially its CNS portfolio—are solid, even if short‑term volatility remains.

Bottom Line Craig Hopkinson’s April 1 trade is a routine, plan‑driven purchase that fits into a larger pattern of balanced insider trading. For investors, this indicates a stable insider position and suggests that, barring major corporate news, Alkermes’ stock will likely continue to benefit from sector momentum rather than insider sentiment alone.